Page 21 - Mylan EpiPen

Conclusions

Mylan’s troubles were however not over as earlier in March

2017 the FDA alerted consumers that Mylan were voluntarily

recalling 13 lots of Mylan’s EpiPen and EpiPen Junior as

there is the potential that these devices may contain a

defective part that may result in the devices’ failure to

activate. June 2017 also saw Senator Chuck Grassley (R-IA)

calculate that Mylan may have overcharged the government

by about $1.27 billion for EpiPens not the agreed $465
million settlement with the DOJ in October 2016.

When questioned on

Mylan's EpiPen price

rise chairman, Robert
Coury, commented:

"….. that he was untroubled. He raised both his middle

fingers and explained, using colorful language, that anyone

criticizing Mylan, including its employees, ought to go
copulate with themselves. Critics in Congress and on Wall

Street, he said, should do the same. And regulators at the

Food and Drug Administration? They, too, deserved a round

of anatomically challenging self-fulfillment."

Charles Duhigg https://www.nytimes.com/2017/06/04/business/angry-about-

epipen-prices-executive-dont-care-much.html